NCT01539473View on ClinicalTrials.gov

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Healthy Volunteers
Interventions
DRUG

TR-701 FA with Tyramine

TR-701 FA 200 mg oral and Tyramine

DRUG

Placebo-controlled withTyramine

Placebo-controlled and Tyramine

Trial Locations (1)

47710

Trius Investigator Site 001, Evansville

All Listed Sponsors
lead

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT01539473 - A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge | Biotech Hunter | Biotech Hunter